BMS 185411

Drug Profile

BMS 185411

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Benzoic acids; Retinoids
  • Mechanism of Action Retinoic acid receptor alpha antagonists; Retinoic acid receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Skin disorders

Most Recent Events

  • 18 Jan 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 18 Jan 2006 Discontinued - Preclinical for Skin disorders in USA (unspecified route)
  • 28 Oct 1999 A preclinical study has been added to the Cancer and Skin Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top